These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 32583766)

  • 1. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.
    Percivalle E; Cambiè G; Cassaniti I; Nepita EV; Maserati R; Ferrari A; Di Martino R; Isernia P; Mojoli F; Bruno R; Tirani M; Cereda D; Nicora C; Lombardo M; Baldanti F
    Euro Surveill; 2020 Jun; 25(24):. PubMed ID: 32583766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
    Harvala H; Mehew J; Robb ML; Ijaz S; Dicks S; Patel M; Watkins N; Simmonds P; Brooks T; Johnson R; Gopal R; Roberts DJ; Zambon M;
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.
    Mehew J; Johnson R; Roberts D; Harvala H
    Euro Surveill; 2020 Nov; 25(45):. PubMed ID: 33183404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A serological assay to detect SARS-CoV-2 seroconversion in humans.
    Amanat F; Stadlbauer D; Strohmeier S; Nguyen THO; Chromikova V; McMahon M; Jiang K; Arunkumar GA; Jurczyszak D; Polanco J; Bermudez-Gonzalez M; Kleiner G; Aydillo T; Miorin L; Fierer DS; Lugo LA; Kojic EM; Stoever J; Liu STH; Cunningham-Rundles C; Felgner PL; Moran T; García-Sastre A; Caplivski D; Cheng AC; Kedzierska K; Vapalahti O; Hepojoki JM; Simon V; Krammer F
    Nat Med; 2020 Jul; 26(7):1033-1036. PubMed ID: 32398876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area.
    Cassaniti I; Percivalle E; Sarasini A; Cambiè G; Vecchio Nepita E; Maserati R; Ferrari A; Corcione A; Di Martino R; Bonetti A; Di Napoli A; Ferrari G; Baldanti F
    Clin Microbiol Infect; 2021 Jun; 27(6):914.e1-914.e4. PubMed ID: 33677083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.
    Thompson CP; Grayson NE; Paton RS; Bolton JS; Lourenço J; Penman BS; Lee LN; Odon V; Mongkolsapaya J; Chinnakannan S; Dejnirattisai W; Edmans M; Fyfe A; Imlach C; Kooblall K; Lim N; Liu C; López-Camacho C; McInally C; McNaughton AL; Ramamurthy N; Ratcliff J; Supasa P; Sampson O; Wang B; Mentzer AJ; Turner M; Semple MG; Baillie K; ; Harvala H; Screaton GR; Temperton N; Klenerman P; Jarvis LM; Gupta S; Simmonds P
    Euro Surveill; 2020 Oct; 25(42):. PubMed ID: 33094713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-based therapies for COVID-19: Can Europe move faster?
    Kazatchkine MD; Goldman M; Vincent JL
    PLoS Med; 2020 May; 17(5):e1003127. PubMed ID: 32369479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19: Main therapeutic options.
    Hachfi W; Ben Lasfar N
    Tunis Med; 2020 Apr; 98(4):299-303. PubMed ID: 32395792
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic.
    Runkel S; Kowalzik F; Gehring S; Winter J; Grandt CL; Marron M; Seifert-Hitzler S; Hitzler WE
    Clin Lab; 2020 Oct; 66(10):. PubMed ID: 33073955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive antibody therapy in COVID-19.
    Abraham J
    Nat Rev Immunol; 2020 Jul; 20(7):401-403. PubMed ID: 32533109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital.
    Sotgiu G; Barassi A; Miozzo M; Saderi L; Piana A; Orfeo N; Colosio C; Felisati G; Davì M; Gerli AG; Centanni S
    BMC Pulm Med; 2020 Jul; 20(1):203. PubMed ID: 32727446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Audio Interview: Capitalizing on Immune Responses to Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
    [No Abstract]   [Full Text] [Related]  

  • 14. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
    Ng DL; Goldgof GM; Shy BR; Levine AG; Balcerek J; Bapat SP; Prostko J; Rodgers M; Coller K; Pearce S; Franz S; Du L; Stone M; Pillai SK; Sotomayor-Gonzalez A; Servellita V; Martin CSS; Granados A; Glasner DR; Han LM; Truong K; Akagi N; Nguyen DN; Neumann NM; Qazi D; Hsu E; Gu W; Santos YA; Custer B; Green V; Williamson P; Hills NK; Lu CM; Whitman JD; Stramer SL; Wang C; Reyes K; Hakim JMC; Sujishi K; Alazzeh F; Pham L; Thornborrow E; Oon CY; Miller S; Kurtz T; Simmons G; Hackett J; Busch MP; Chiu CY
    Nat Commun; 2020 Sep; 11(1):4698. PubMed ID: 32943630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The convalescent sera option for containing COVID-19.
    Casadevall A; Pirofski LA
    J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
    [No Abstract]   [Full Text] [Related]  

  • 16. Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.
    Wang QJ; Yao YZ; Song JS; Wang Q; Xu LY; Bao ZJ; Mao DW; Zhou JH; Zhang ZE; Wang Y; Li YW; Wang HP; Li L; Pan HY; Zhang GQ; Li SB
    BMC Infect Dis; 2020 Nov; 20(1):818. PubMed ID: 33167900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
    DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
    J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
    Lu Y; Wang Y; Zhang Z; Huang J; Yao M; Huang G; Ge Y; Zhang P; Huang H; Wang Y; Li H; Wang W
    J Immunol Res; 2020; 2020():9465398. PubMed ID: 33134398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
    JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.
    Meschi S; Colavita F; Bordi L; Matusali G; Lapa D; Amendola A; Vairo F; Ippolito G; Capobianchi MR; Castilletti C;
    J Clin Virol; 2020 Aug; 129():104539. PubMed ID: 32679298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.